RA
PTGX icon

Rise Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Rise Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-224
Closed -$14.9K – 1114
2025
Q3 		$14.9K Hold
224
– – 0.01% 761
2025
Q2 		$12.4K Hold
224
– – ﹤0.01% 862
2025
Q1 		$10.8K Buy
+224
New +$9.39K ﹤0.01% 914

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Rise Advisors's PTGX Position: Q4 2025 in Review

Rise Advisors sold out of Protagonist Therapeutics (PTGX) in Q4 2025, closing a stake of 224 shares — an estimated $14.9K sold.

Rise Advisors first reported a position in PTGX in Q1 2025 and held it in 3 quarters. The position peaked at $14.9K in Q3 2025. 316 funds tracked by Wall St. Rank hold PTGX as of Q4 2025.

  • Rise Advisors reported no remaining Protagonist Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Rise Advisors sold 224 Protagonist Therapeutics shares in Q4 2025, an estimated $14.9K.
  • Rise Advisors first reported a position in Protagonist Therapeutics in Q1 2025 and held it in 3 quarters.
  • Rise Advisors's Protagonist Therapeutics position peaked at $14.9K in Q3 2025.
  • 316 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.